Mentor Announces Initial Patient Injections in Phase III Study for PurTox(R) Botulinum Toxin Type A
Tuesday July 3, 9:00 am ET
SANTA BARBARA, Calif.--(BUSINESS WIRE)--Mentor Corporation (NYSE:MNT - News), a leading supplier of medical products for the global aesthetic market, announced today that initial patient enrollment and treatment in its pivotal Phase IIIa study of PurTox® for the reduction of glabellar rhytides (frown lines) by intramuscular injection took place on June 29, 2007. PurTox is a purified botulinum toxin type A neurotoxin. Mentor had previously announced that it received Food and Drug Administration (FDA) approval for its Phase IIIa study protocol and that it anticipated the initiation of this study during its first fiscal quarter.
Joshua H. Levine, President and Chief Executive Officer of Mentor Corporation, commented, "This is a significant step in our long-term growth strategy to expand our presence in facial aesthetic medicine. We believe these Phase III clinical studies will support a successful FDA approval and validate the benefits of a purified toxin."
"We are very excited to be participating in the Phase III studies," said Dr. Corey Maas, Principal Investigator and head of The Maas Clinic in San Francisco. "The early results of the safety and efficacy of PurTox demonstrated in the Phase II study are extremely promising as they relate to aesthetic outcomes for our patients."
In addition, Mentor continues to make substantial progress in its Phase I clinical study for the therapeutic indication of treatment of pain associated with adult onset spasmodic torticollis/cervical dystonia. Multiple cohorts of patients have been treated and follow-up is ongoing.
About Mentor Corporation
Founded in 1969, Mentor Corporation is a leading supplier of medical products for the global aesthetic market. The Company develops, manufactures and markets innovative, science-based products for surgical and non-surgical medical procedures that allow patients to retain a more youthful appearance and improve personal well-being. The Company's website is www.mentorcorp.com. |
